Data presented at Digestive Disease Week (DDW) 2025 demonstrated safety and treatment success in patients treated for recurrent C. Diff…
Ferring expands production of ADSTILADRIN with new Parsippany, NJ, facility, adding to existing manufacturing sites in Kuopio, Finland Capacity expansion…
First results from a Phase 3 trial conducted across 25 centers in Japan highlight Ferring’s ongoing commitment to establish ADSTILADRIN…
Ferring is encouraged to see President Trump’s Executive Order aimed at finding ways to make in vitro fertilization (IVF) more…
Independent experience at three Mayo Clinic sites and real-world outcomes data with ADSTILADRIN in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive…
FDA approved to prevent recurrent C. difficile infection (rCDI), REBYOTA is widely available with a strong drug supply and dedicated…
Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an…
Anesthetic and Analgesic Drug Products Advisory Committee will hold the meeting on January 10, 2025 SI-6603 is an investigational product…
Parsippany, NJ – November 13, 2024 – Ferring Pharmaceuticals is grateful to New Jersey and Minnesota for recognizing November as…
Real-world analyses evaluated the effectiveness of REBYOTA in patients with GI conditions or comorbidities as well as those who received…